sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Lebrikizumab

Medicine · Interleukin-13 Antagonist

Lebrikizumab

EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription…

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription…
Do not take if
EBGLYSS is contraindicated in patients with prior serious hypersensitivity to lebrikizumab-lbkz or any excipients of EBGLYSS.

What it is used for

EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.

Side effects, and when to stop

The following adverse reactions are described elsewhere in the labeling:

  • Hypersensitivity
  • Conjunctivitis and Keratitis

Who should not take it

EBGLYSS is contraindicated in patients with prior serious hypersensitivity to lebrikizumab-lbkz or any excipients of EBGLYSS.

Storing it

Storage and Handling

Store refrigerated at 2°C to 8°C (36°F to 46°F).

If necessary, EBGLYSS can be stored at room temperature up to 30°C (86°F) for up to 7 days in the original carton. Dispose of EBGLYSS that has been left at room temperature for longer than 7 days.

Store in the original carton to protect from light until use.

Do not freeze. Do not use EBGLYSS if it has been frozen.

Do not shake.

Do not microwave, run hot water over it, or leave it in direct sunlight.

Not made with natural rubber latex.

Discard the EBGLYSS single-dose prefilled pen or prefilled syringe with needle shield after use in a puncture-resistant container.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Lebrikizumab; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/lebrikizumab

APA 7th

sofidex. (2026, August 3). Lebrikizumab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/lebrikizumab

AMA 11th

Lebrikizumab. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/lebrikizumab

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.